∂È̤ÏÂÈ·: ÕÏ. ¶·‡ÏÔ˘1, ¡. √ÈÎÔÓÔÌ¿Î˘2, £. ¶·Ó·Ófi˜3, º. ¶ÂÙ˙ÂÚ›‰Ë4, ™. ¶¤ÙÚÔ‚·5
1Managing Partner BIONOVA, 2Consultant Bio Business Analysis Unit, 3Consultant technology transfer Unit and alernate NCP, 4Pharmacology Consultant 5Science Editor Advanced Cell Technology Completes Acquisition of Mytogen, Inc.
lead to a significant increase in quality of signed on July 31, 2007 subject to certain life for the patient. The company applied the treatment of heart failure will begin closing conditions. ACTC issued a total of Phase II clinical trials shortly, while two of approximately 8.2 million restricted shares and assumed certain Mytogen liabilities.
"end-of-Phase I" data and will allow million shares of restricted common stock with a Phase II human clinical trial.
preclinical studies. We expect to file IND's human clinical trial for the treatment of Phase III double-blind, placebo-controlled years of experience in clinical trial and FDA parallel group trial, in which approximately III trial. The Myoblast Program may prove stem cells. This stem cell therapy involves particularly beneficial for patients that and have a high risk of heart failure.
trough sitting SBP and trough sitting DBP, medicine and we are excited to join their cells over a period of two to three weeks.
President and Chief Scientific Officer of active-controlled, parallel group trial, in Mytogen, Inc. "By merging with Advanced scarred heart tissue through the use of a clinical trials and bring our therapies to William M. Caldwell, IV, Chairman and CEO safely in over 40 patients. Safety of the "The completion of this acquisition marks studies. While the Phase I human clinical therapy, the clinical data from those trials GeneGo, Inc. in Multi-
Bristol-Myers Squibb to Buy Partner Adnexus
Year Deal with Bristol-
Therapeutics for $430 Million
Myers Squibb Company
GeneGo, Inc., the leading systems biology Bristol-Myers Squibb Company and Adnexus Therapeutics announced today the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire privately held Adnexus Therapeutics, developer of a new therapeutic class of biologics called Adnectins. The acquisition of Adnexus will help advance Bristol-Myers Squibb's biologics strategy across multiple therapeutic areas and includes a Myers Squibb will have the ability to start Phase I oncology biologic, Angiocept. Adnexus Therapeutics will become a subsidiary of Bristol-Myers Squibb and remain based in Waltham, Massachusetts. Under the terms of the agreement Bristol-Myers Squibb will acquire all of Adnexus' issued and outstanding shares of capital stock and stock equivalents in an all-cash transaction for a gross purchase price of $430 million, with the net purchase price being $415 million after deducting Adnexus' net cash balance at closing. In addition, there is an earn-out structure which could result in Bristol-Myers Squibb paying an additional amount of approximately $75 million, in three increments of approximately $25 million each, in the event certain development and regulatory milestones are achieved. The closing of the transaction is subject to customary regulatory approvals. Adnectins are a proprietary class of targeted biologics developed by Adnexus.
PROfusion(TM) is Adnexus' proprietary protein design engine, with which trillions of their own internal interaction data in the protein variations can be engineered at one time. Angiocept is an Adnectin designed to be an anti-angiogenic drug and is currently in Phase I development. AstraZeneca PLC to Pay Up to $310 Million for Verus Pharmaceuticals'
Asthma Programs
V erus Pharmaceuticals, Inc., a pe- rsements, and a potential earn-out programs that hold the potential to help millions of children suffering from asthma and may positively impact their quality of "We are excited to have completed this respiratory primary care at AstraZeneca.
programs. Included in the transaction are chronic childhood illness affecting almost the North American rights to a Captisol(R) States. Approximately 6.5 million children rapidly expanding patient population," said Robert W. Keith, President and Chief cation), a customized version of eFlow(R) (novel nebulizer delivery device) for use transaction allows us to refocus our time related atopic diseases and conditions." "AstraZeneca is proud to be a part of cost of treating asthma in children under


Application proforma.qxd (page 1)

S u s t a i n a b l e s c h o o l s a w a r d This document is a copy of the Sandwell Sustainable School self-evaluation audit tool and lists the evidence that will be required to become a Sustainable School. Using the on-line application form at schools can identify where sustainable development education takes place in teaching, good practice and manageme

Registration dossiers autorizados april 2010

R E G IS T R A T I O N D OS S I E R S A V A I L A B L E RE TAI L MA RKE T (WHOL ESAL ER S AND PH ARM AC IES) MOLECULE REFERENCE PRODUCT Acyclovir Dexketoprofen Solution for injection/Concentrate for solution for Doxazosin Fluoxetine Gabapentin Glimepiride Glucosamine Sulphate Ibuprofen-lysine Memantine Mirtazapine Pa

© 2008-2018 Medical News